The objective of the current study was to evaluate the association between tobacco use, symptom expression, and coping strategies in patients with advanced cancer. METHODS: The authors prospectively enrolled patients with advanced cancer and collected data regarding patient demographics, cancer diagnosis, morphine equivalent daily dose, cigarette smoking status using the Behavioral Risk Factor Surveillance System, symptom expression as measured by the Edmonton Symptom Assessment System, the Cut down/Annoyed/Guilty/Eye opener alcoholism questionnaire, the Screener and Opioid Assessment for Patients with Pain-short form survey, and the Brief COPE Questionnaire. RESULTS: Among 399 patients, 195 (49%) were never-smokers, 158 (40%) were former smokers, and 46 (11%) were current smokers. The most common malignancies were gastrointestinal (21%) and breast (19%). Current smokers demonstrated significantly higher pain scores at the time of consultation compared with former or never-smokers (mean 6.4 vs 5.9 vs 5.1, respectively; P=.015), demonstrated increased morphine equivalent daily dose (median 90 mg/day vs 60 mg/day vs 50 mg/day, respectively; P=.002), were more likely to screen as positive on the Cut down/Annoyed/Guilty/Eye opener questionnaire (33% vs 24% vs 8.7%, respectively; P<.0001) and were more likely to screen as positive (≥4) on the Screener and Opioid Assessment for Patients with Pain-short form survey (74% vs 13% vs 9.3%, respectively; P<.0001). Compared with former and never-smokers, current smokers were significantly more likely to cope maladaptively with substance use (P=.02), denial (P=.007), and self-blame (P<.0001). CONCLUSIONS: Among patients with advanced cancer, current and former smokers appear to be significantly more likely to have higher pain expression and thus require higher opioid doses, and to have more risk factors for using opioids in a nonprescribed manner. The results of the current study highlight the need to provide closer monitoring and increased psychosocial support for patients with cancer who smoke while receiving chronic opioid therapy. Cancer 2019;125:153-160.
INTRODUCTION
A national epidemic of substance/opioid use disorder is affecting the general population. 1 In the past, the treatment of cancer pain was inadequate, resulting in health care providers advocating for the more liberal prescription of opioids to treat pain to the standards of the Joint Commission. 2 More recently, restrictions have been placed on opioid prescriptions, even in patients with cancer. 3 Experts have advocated for screening for the risk of substance/opioid use disorder prior to the prescription of opioids; however, to our knowledge, there is no single assessment that can be recommended as the gold standard. 4 According to the Centers for Disease Control and Prevention, in 2015, the prevalence of smoking in the adult population in the United States was 15.1%. 5 Smoking is noted to be more common among individuals with mental health problems, those with a history of alcoholism or nonmedical drug use, individuals with a criminal record, and the homeless. 6 In population-based studies, smokers generally report more intense, widespread pain compared with never-smokers. [7] [8] [9] Persistent smoking despite a diagnosis of cancer has been associated with increased pain expression and decreased function. [10] [11] [12] In the chronic pain population, tobacco users are reported to be at an increased risk of becoming opioid users, and vice versa. [13] [14] [15] [16] Smokers also are reported to be prescribed morphine by health care providers more frequently and at higher opioid doses after surgery when compared with never-smokers. [17] [18] [19] In a preliminary retrospective study examining tobacco use and symptoms in patients with advanced cancer, our group reported that a significantly higher percentage of smokers demonstrated increased pain scores and were more likely to be prescribed opioids with a morphine DOI: 10.1002/cncr.31783, Received: January 19, 2018 ; Revised: July 6, 2018; Accepted: August 29, 2018 ; Published online October 23, 2018 in Wiley Online Library (wileyonlinelibrary.com)
Cancer January 1, 2019 equivalent daily dosing (MEDD) of ≥30 mg/day prior to palliative care consultation (44% vs 26%; P=.01). 20 The current prospective survey was conducted to examine the association between tobacco use in patients with advanced cancer with symptom expression as measured by the Edmonton Symptom Assessment System (ESAS) 21 and the use of strong opioids. The World Health Organization cancer pain relief ladder defines strong opioids such as morphine and other analgesics such as hydromorphone, oxycodone, fentanyl, methadone, and oxymorphone with an equivalent MEDD of ≥30 mg/day. We also examined the association between tobacco use and the risk of using medications in a nonprescribed manner using the Screener and Opioid Assessment for Patients with Pain-short form (SOAPP-SF), 22 a history of alcoholism as assessed by the Cut down/Annoyed/Guilty/Eye opener (CAGE) questionnaire, 23 maladaptive coping strategies using the Brief COPE questionnaire, 24 and the palliative care physician's clinical assessment of a patient's risk of chemical coping and somatization.
MATERIALS AND METHODS
We prospectively screened 490 consecutive patients with cancer who were evaluated in an outpatient supportive care center from 2015 through 2016. A total of 441 patients who attended at least 1 follow-up visit in our outpatient supportive care clinic were eligible to participate in the study. Eligible patients were required to have a diagnosis of advanced cancer and be aged ≥18 years. Advanced cancer was defined as locally advanced, metastatic, or locally recurrent disease for solid tumors, and primary progressive or recurrent/refractory disease for hematologic malignancies. Patients with locally advanced cancer who received curative surgery or definitive chemoradiation were excluded. Patients with cancer who used only non-cigarette smoking tobacco products including chewing tobacco, snuff or dip, pipes, cigars, or electronic cigarettes also were excluded.
The institutional review board at The University of Texas MD Anderson Cancer Center in Houston approved this prospective study.
Data Collection
We collected baseline patient demographics including age, sex, ethnicity, and marital status. Data regarding the primary cancer type including the date of diagnosis of advanced cancer and location of the primary cancer as well as stage of disease at the time of the initial palliative care consultation and follow-up were recorded.
Cigarette smoking status was determined using questions from the Behavioral Risk Factor Surveillance System (BRFSS) by the US Centers for Disease Control and Prevention. 25 Consistent with Behavioral Risk Factor Surveillance System categories, patients were grouped into 3 categories: 1) current smokers; 2) former smokers; and 3) never-smokers. An individual who reported smoking at least 100 cigarettes in his or her lifetime and who at the time of the survey smoked either every day or some days was defined as a "current smoker." A respondent who reported smoking at least 100 cigarettes in his or her lifetime and who at the time of the survey did not smoke was defined as a "former smoker." A respondent who reported never having smoked 100 cigarettes in his or her lifetime was defined as a "never-smoker."
Assessments including the Edmonton Symptom Assessment System (ESAS), 21 the CAGE alcoholism screening questionnaire, 23 the SOAPP-SF, 22 the brief COPE questionnaire, 26 and the patient's Zubrod performance score were collected.
The ESAS scores the severity of 10 symptoms (pain, fatigue, nausea, depression, anxiety, drowsiness, dyspnea, anorexia, feeling of well-being, and insomnia) on a numerical scale from 0 to 10 in which 0 indicates no symptoms and 10 indicates the worst possible symptom intensity. 21 The CAGE questionnaire is a validated 4-item screening tool for a history of alcoholism. 23 A score of ≥2 is considered positive and the questionnaire has been reported to be approximately 85% sensitive and 90% specific for the diagnosis of alcohol abuse and/or dependence. 27 This questionnaire asks the following questions: 1) Have you ever felt the need to Cut down on drinking?; 2) Have you ever felt Annoyed by criticism of your drinking?; 3) Have you ever had Guilty feelings about your drinking?; and 4) Have you ever taken a morning Eye opener?
The SOAPP (version 1.0) (Inflexxion, Newton, Massachusetts) is a screening tool developed to monitor patients receiving long-term opioid therapy. 22 Based on factor analysis of the SOAPP questionnaire, 5 factors were noted to be critical in determining an individual's risk of nonmedical use of opioids and include: 1) mood swings; 2) nicotine dependence; 3) personal and/or family history of substance/opioid use disorder; 4) history of legal problems; and 5) craving medication. These factors were used to develop the brief 5-item SOAPP-SF. The SOAPP-SF consists of 5 items rated on a 5-point scale in which 0 indicates never, 1 indicates seldom, 2 indicates sometimes, 3 indicates often, and 4 indicates very often;
Cancer January 1, 2019 a total score of ≥4 is considered positive (ie, high-risk patients). The SOAPP-SF has a sensitivity of 0.86 and a specificity of 0.67 for the risk of aberrant drug use. 22 The Brief COPE 24 is a self-reported, validated, 28-item questionnaire that evaluates state coping, which is the manner in which an individual copes in response to a specific situation (ie, the cancer diagnosis). It consist of 14 subscales (2 items per subscale) measuring the following: self-distraction, active coping, denial, substance use, use of emotional support, use of instrumental support, behavioral disengagement, venting, positive reframing, planning, humor, acceptance, religion, and self-blame. Cronbach alphas range from .50 to .90 for the Brief COPE subscales. Each single item is scored along a 4-point scale with the following options: 1 (I usually don't do this at all); 2 (I usually do this a little bit); 3 (I usually do this a medium amount); and 4 (I usually do this a lot). The following 8 subscales are classified as adaptive strategies: active coping, planning, positive reframing, acceptance, humor, religion, use of emotional support, and use of instrumental support. The remaining 6 subscales are considered to be maladaptive and include self-distraction, denial, venting, substance use, behavioral disengagement, and self-blame. 28, 29 The maximum score for the 14 subscales is 8 points, with a higher score indicating greater use of a specific coping strategy. The Brief COPE has been used previously to assess styles of coping in patients with breast cancer, 30 caregivers of patients with Alzheimer disease, 31 and symptomatic men who are positive for the human immunodeficiency virus. 32 We collected the type of analgesics prescribed and determined the MEDD. In addition, we asked board-certified palliative care physicians to determine whether the patient was at risk of chemical coping or somatization. Chemical coping has been defined as the nonmedical or excessive use of opioids and/or other psychotropic drugs to cope with life stressors. 33, 34 Somatization has been defined as a syndrome of unexplained physical symptoms that are distressing and may be caused or exacerbated by emotional distress. 35 Prior to initiation of the study, the principal investigator met with all physicians in the palliative care department to review the definition of maladaptive opioid chemical coping and somatization and they reviewed several case presentations together to highlight the concepts and form consensus regarding classifying the risk of chemical coping and somatization as either no risk, probable risk, or high risk.
Statistical Analysis
Summary statistics are provided to describe the demographic and clinical characteristics of the patients according to smoking status. Variables to be analyzed included smoking status; physician diagnosis of chemical coping; CAGE positivity; symptom burden (as measured by the ESAS); opioid dose in MEDD; risk of substance/opioid use disorder (using the SOAPP-SF); physician assessment of somatization; patient-reported chemical coping and craving; and demographic variables such as age, sex, ethnicity, cancer type, educational level, cancer stage, and Zubrod performance score. Completed and Available for Analysis (N=399)
• Selected for a different study (n=29)
• Not Approved by Physician (n=6)
• Other ComorbidiƟes (n=3)
• Non-English Speaking (n=11)
• Declined due to illness (n=8)
• Refused (n=7)
• Dislikes ParƟcipaƟon in Research (n=26)
• Declined to complete survey (n=1)
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The chi-square test or Fisher exact test, whichever was appropriate, was used to examine the differences in the categorical variables of interest (eg, sex) between the different smoking status groups (active smoker, former smoker, or never-smoker). The Wilcoxon rank sum test was used to examine the differences in continuous variables of interest (eg, patient-reported chemical coping and craving) among the different smoking status groups. All computations were performed using SAS statistical software (version 9.3; SAS Institute Inc, Cary, North Carolina). A P value <.05 was considered to be statistically significant.
RESULTS
A total of 399 consecutive patients completed a comprehensive questionnaire evaluating their history of tobacco use, symptom burden, risk of nonmedical drug use, and assessment of coping (Fig. 1) . Table 1 summarizes patient characteristics according to smoking status. Among the 399 patients, 46 (11%) were current smokers, 158 (40%) were former smokers, and 195 (49%) were never-smokers. The mean age (±standard deviation) of the active smokers was 51.6 ± 12.9 years, which was significantly younger than that of never-smokers (55.4 ± 12.6 years) and former smokers (59.3 ± 10.3 years). The majority of patients were female (223 patients; 55.9%), and were more likely to be never-smokers (P=.005). Active and former smokers were noted to have significantly less education than never-smokers (P<.0001). Table 2 summarizes pain scores as measured by the ESAS at the time of consultation and at follow-up, opioid use, CAGE positivity, and SOAPP-SF positivity according to smoking status. Active smokers expressed significantly higher pain scores at the time of consultation compared with former or never-smokers (mean, 6.4 vs 5.9 vs 5.1, respectively; P=.015) and at the first follow-up visit (mean, 4.7 vs 4.4 vs 3.5, respectively; P=.0045). However, the change in pain scores between follow-up and consultation were not significantly different among the 3 groups (P=.92). The median MEDD was significantly higher for active smokers compared with former smokers and never-smokers (90 mg/day vs 60 mg/day vs 50 mg/ day, respectively; P=.002). Active smokers were found to be significantly more likely to screen positive using the CAGE questionnaire compared with former and never-smokers (32.6% vs 24.1% vs 8.7%, respectively; P<.0001) as well as the SOAPP-SF survey (73.9% vs 12.7% vs 9.3%, respectively; P≤.0001). Symptoms other than pain as measured by the ESAS were not found to be significantly different among the 3 groups. Table 3 summarizes the assessment of coping by the Brief COPE inventory based on smoking status. Cancer January 1, 2019
Compared with former and never-smokers, current smokers were significantly more likely to cope with maladaptive strategies including substance use (P=.02), denial (P=.007), and self-blame (P<.0001), whereas both current and former smokers were significantly more likely to use venting (P=.04).
Palliative care physicians rated a greater percentage of patients as being at high risk of chemical coping (6.5% vs 2.5% vs 1.5%, respectively) and a nonsignificant trend was noted for physician perception of increased risk of somatization in active smokers versus former or never-smokers (P=.09) ( Table 4) .
DISCUSSION
In the current prospective study of patients with advanced cancer who were seen in an ambulatory supportive care clinic, patients who were current smokers rated their pain higher than former smokers, and both expressed a higher degree of pain intensity compared with never-smokers. It is interesting to note that significantly higher pain expression persisted at follow-up, whereas the reductions in pain scores were equal among the 3 groups. The percentages of patients receiving strong opioids were not significantly different between the current smokers, former smokers, or never-smokers; however, the MEDD was noted to be significantly higher in current smokers compared with former smokers and both groups had a higher MEDD compared with never-smokers. In addition, the frequency of patients who were positive by the CAGE or SOAPP-SF surveys was higher in patients who currently smoked compared with former smokers and both were higher than in never-smokers. Patients who actively smoked or had a history of smoking were found to be significantly more likely to use maladaptive coping Maladaptive, mean ± SD Substance abuse 2.2 ± 0.8 2.5 ± 1.2 2.2 ± 0.8 2.1 ± 0.6 .02 Self-blame 2.9 ± 1.4 3.8 ± 2.0 2.9 ± 1.5 2.6 ± 1.1 <.0001 Denial 2.6 ± 1.3 3.1 ± 1.6 2.6 ± 1.2 2.6 ± 1.2 .007 Venting 3.8 ± 1.5 4.2 ± 1.6 3.9 ± 1.5 3.6 ± 1.4 .04 Behavioral disengagement 2.3 ± 0.9 2.5 ± 0.9 2.3 ± 0.9 2.3 ± 0.9 .12 Self-distraction 4.9 ± 1.6 5.3 ± 1.5 4.7 ± 1.7 4.9 ± 1.6 .13 Adaptive, mean ± SD Active coping 6.0 ± 1.7 6.3 ± 1.5 6.2 ± 1.6 5.7 ± 1.7 .04 Emotional support 6.8 ± 1.6 6.7 ± 1.5 6.8 ± 1.6 6.8 ± Cancer January 1, 2019 strategies such as substance abuse, denial, venting, and self-blame as characterized by the Brief COPE inventory. In addition, palliative care physicians stratified a significantly greater percentage of current and former smokers as being at high risk of chemical coping compared with never-smokers.
To the best of our knowledge, it is unclear what accounts for the higher pain expression. Physicians did note a weak trend for an increased risk of somatization in patients who had a history of smoking or were current smokers, which may account for the increased pain expression. However, the frequency of somatization was lower when compared with another study that included patients with noncancer pain, 35 which could suggest an underdiagnosis of somatization in the population of patients with advanced cancer in the current study. Herein, the assessment of patients occurred at the time of first follow-up and physicians may have been reluctant to diagnose somatization in a patient with whom they have a limited relationship. Alternatively, patients who are opioid seeking may have a higher pain expression, which may contribute to higher pain scores.
Potentially addictive substances such as nicotine, alcohol, and opioids activate similar neuronal systems in the mesocorticolimbic pathways, 36 and some studies have implicated the dopamine reward system. 37 Chronic exposure to addictive substances leads to neuroadaptive changes associated with addiction and may lead to cross-sensitization to other addictive substances. 36, 38 Patients with cancer often experience high physical and psychological symptom burdens during the initial disclosure of the cancer diagnosis and disease progression, when experiencing complications of therapy, and at the end of life. Past maladaptive chemical coping behavior such as tobacco or alcohol use may resurface as nonmedical drug use in patients with cancer as they experience physical and psychological pain. Automatic opioid escalation based on a patient's subjective ratings of pain may result in placing patients at an increased risk of opioid toxicity and propagate the nonmedical use of opioids. Based on the results of the current study, patients with cancer who have a history of smoking or who are actively smoking are at an increased risk of nonmedical drug use and therefore the judicious titration of opioids based on functional status, in addition to subjective ratings of pain, with increased psychosocial support is warranted.
Prior to the prescription of opioids, experts in pain management recommend screening for the risk of substance/opioid use disorder with tools such as the CAGE or SOAPP questionnaires. 4 It is critical that health care providers maintain a nonjudgmental attitude when assessing patients with cancer who are at risk of chemical coping and be mindful that patients who screen positive or at high risk of nonmedical drug use may, in the future, be fully compliant and that patients who initially may screen negative still may be at risk of substance/opioid use disorder. Longitudinal studies are needed to determine whether risk stratification strategies prior to the prescription of opioids among patients with cancer lead to better clinical outcomes.
As a group, acceptance was the most frequently used coping strategy in the current study population of patients with advanced cancer, a finding that is similar to those of other published studies. 39, 40 In general, our population endorsed adaptive coping strategies over maladaptive strategies; however, coping strategies may change during the course of the illness, as reported by other groups. 30 It is interesting to note that, in the current study, patients who were active or former smokers were found to be more likely to use maladaptive coping strategies compared with never-smokers. Patients with advanced cancer may have been reluctant to disclose using substance abuse as a coping strategy or may not have had the insight to be aware that they were chemically coping, resulting in underreporting. Therefore, more research is needed. Cancer January 1, 2019
A limitation of the current prospective study is the small sample size of current smokers, which limited the power to detect significant differences between groups. In addition, the CAGE questionnaire is a screening tool and is not diagnostic for alcoholism, which requires a formal evaluation and diagnosis using the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. The link between tobacco, alcohol, and chemical coping with the nonmedical use of opioids needs further exploration in longitudinal studies.
CONCLUSIONS
The results of the current prospective study of patients with advanced cancer suggest that current and former smokers are significantly more likely to have higher pain expression and increased opioid requirements than never-smokers. In addition, patients with advanced cancer who smoke or have a history of smoking appear to be more likely to screen positive in both the CAGE and SOAPP-SF questionnaires, which places them at an increased risk of substance/opioid use disorder. In patients with cancer, a history of smoking, especially active smoking, is an indicator of patients who are at an increased risk of maladaptive coping. Patients with a smoking history who are receiving chronic opioid therapy for cancer pain may require more frequent monitoring and increased psychosocial support to assist with coping with cancer.
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